scout
|Videos|June 1, 2020

Role of Novel Subcutaneous Daratumumab in Multiple Myeloma

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME